Citadel Advisors
AVDL

Citadel Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Citadel Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-133,300
Closed -$2.87M – 12955
2025
Q4 		$2.87M Sell
133,300
-65,400
-33% -$1.27M ﹤0.01% 5249
2025
Q3 		$3.03M Buy
198,700
+21,700
+12% +$282K ﹤0.01% 5289
2025
Q2 		$1.57M Buy
177,000
+22,500
+15% +$198K ﹤0.01% 6175
2025
Q1 		$1.21M Sell
154,500
-204,000
-57% -$1.71M ﹤0.01% 6534
2024
Q4 		$3.77M Buy
358,500
+202,600
+130% +$2.46M ﹤0.01% 4441
2024
Q3 		$2.04M Sell
155,900
-55,100
-26% -$839K ﹤0.01% 5487
2024
Q2 		$2.97M Sell
211,000
-36,500
-15% -$595K ﹤0.01% 4583
2024
Q1 		$4.18M Buy
247,500
+61,300
+33% +$913K ﹤0.01% 4223
2023
Q4 		$2.63M Buy
186,200
+10,100
+6% +$119K ﹤0.01% 4883
2023
Q3 		$1.81M Sell
176,100
-75,700
-30% -$1.01M ﹤0.01% 5397
2023
Q2 		$4.15M Sell
251,800
-42,400
-14% -$551K ﹤0.01% 3941
2023
Q1 		$2.69M Sell
294,200
-425,300
-59% -$3.5M ﹤0.01% 4821
2022
Q4 		$5.15M Sell
719,500
-25,600
-3% -$180K ﹤0.01% 3813
2022
Q3 		$3.73M Buy
745,100
+93,500
+14% +$515K ﹤0.01% 4375
2022
Q2 		$1.59M Buy
651,600
+603,600
+1,258% +$2.48M ﹤0.01% 6020
2022
Q1 		$328K Buy
48,000
+16,400
+52% +$113K ﹤0.01% 10385
2021
Q4 		$255K Sell
31,600
-6,600
-17% -$60.3K ﹤0.01% 11293
2021
Q3 		$374K Sell
38,200
-38,900
-50% -$306K ﹤0.01% 10563
2021
Q2 		$519K Sell
77,100
-1,200
-2% -$9.53K ﹤0.01% 9990
2021
Q1 		$708K Buy
78,300
+31,600
+68% +$255K ﹤0.01% 8918
2020
Q4 		$312K Sell
46,700
-2,400
-5% -$15K ﹤0.01% 9004
2020
Q3 		$247K Buy
49,100
+14,100
+40% +$103K ﹤0.01% 8456
2020
Q2 		$283K Sell
35,000
-2,300
-6% -$20.3K ﹤0.01% 7999
2020
Q1 		$296K Buy
37,300
+26,300
+239% +$202K ﹤0.01% 7361
2019
Q4 		$83K Sell
11,000
-3,200
-23% -$16.9K ﹤0.01% 8614
2019
Q3 		$59K Sell
14,200
-7,400
-34% -$18.5K ﹤0.01% 8657
2019
Q2 		$62K Buy
+21,600
New +$37.1K ﹤0.01% 8665
2018
Q4 		– Sell
-18,700
Closed -$82K – 9080
2018
Q3 		$82K Sell
18,700
-8,700
-32% -$47K ﹤0.01% 8646
2018
Q2 		$168K Buy
27,400
+2,000
+8% +$14K ﹤0.01% 8011
2018
Q1 		$185K Buy
25,400
+9,000
+55% +$79.2K ﹤0.01% 7413
2017
Q4 		$134K Buy
16,400
+4,900
+43% +$46K ﹤0.01% 7319
2017
Q3 		$121K Buy
+11,500
New +$110K ﹤0.01% 6967
2016
Q4 		– Sell
-11,600
Closed -$144K – 7235
2016
Q3 		$144K Buy
+11,600
New +$152K ﹤0.01% 6495

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's AVDL Position: Q1 2026 in Review

Citadel Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 770,232 shares — an estimated $16.6M sold.

Citadel Advisors first reported a position in AVDL in Q4 2014 and held it in 39 quarters. The position peaked at $31.5M in Q2 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Citadel Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 770,232 Avadel Pharmaceuticals shares in Q1 2026, an estimated $16.6M.
  • Citadel Advisors first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 39 quarters.
  • Citadel Advisors's Avadel Pharmaceuticals position peaked at $31.5M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.